Nutanix, Inc. (NTNX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nutanix, Inc. on December 16, 2025. The filing discloses a significant capital allocation event: the entry into an Accelerated Share Repurchase (ASR) agreement.
Key Financial Metrics and Transaction Details
- Transaction Type: Accelerated Share Repurchase (ASR) of Class A Common Stock.
- Total Value: $300 million.
- Initial Share Delivery: Approximately 4,972,032 shares expected on December 17, 2025.
- Funding Source: Existing cash on hand.
- Counterparty: Bank of America, N.A.
- Settlement Timeline: Expected before the end of January 2026.
The final number of shares repurchased will be determined by the volume-weighted average price of the stock during the term, less a discount. The filing does not provide specific revenue, profit, cash flow, or debt metrics for the period, as this report focuses solely on the share repurchase event.
Material Changes and Outlook
The primary material change is the reduction of outstanding shares and the deployment of $300 million in cash. Management views this as a return of capital to stockholders while maintaining the ability to innovate and invest in the business. The final share count is contingent on market performance during the ASR term.
Risks and Contingencies
- Market Price Risk: The final number of shares repurchased depends on the market price of the Common Stock during the ASR term.
- Settlement Variability: At settlement, the Dealer may deliver additional shares, or the Company may be required to make a cash payment or deliver shares to the Dealer.
- Forward-Looking Statements: Actual results may differ materially from expectations due to factors beyond the Company's control, as detailed in the Form 10-K filed on September 24, 2025.
Investor Verification Checklist
- Verify the final settlement date and total share count upon completion of the ASR in January 2026.
- Confirm the impact of the $300 million cash outflow on the Company's liquidity position in the next quarterly report.
- Review the Form 10-K (filed September 24, 2025) for comprehensive risk factors and financial health context.
- Monitor subsequent filings for any adjustments to the transaction terms or early termination.